Croda is a successful global company with operations in 37 countries, selling into the three core markets of Consumer Care, Life Sciences and Performance Technologies.
Energy from non-fossil fuels25.0%
Organic raw materials from bio-based sources67.0%
Hectares of land saved above our 2019 baseline16,455.0
Number of lives improved25.0million people
Our business continues to grow and strengthen through our:
Purpose-led people and culture: Using Smart science to improve lives™, aligned with our ambitious commitment to be the most sustainable supplier of innovative ingredients.
Structure and focus on fast-growing sectors: Consumer focused business, investing in growing and harnessing technology and know-how within these fast growth areas. Strongly positioned in high-growth niches and well aligned with growing consumer demand for sustainability.
Dynamic innovation engine: Open approach to innovation with 500 partners working on over 100 projects increasingly focused on sustainability.
Sustainability focus: meeting the growing consumer and customer need for sustainable, high performance ingredients.
Case Study: Pioneering science - Croda supports Pfizer-BioNTech COVID-19 vaccine
Avanti, a company we acquired in 2020, has a strong track record in supplying R&D quantities of lipid-based drug delivery technologies to pharmaceutical companies including those developing mRNA drugs. When the COVID-19 pandemic hit, mRNA vaccine candidates were fast-tracked to Phase II clinical trials and Avanti became a key supplier. Due to increased demand, Avanti needed to ramp up its R&D capability and lipid production capacity quickly.
Our team rapidly re-designed the component production process, scaling up GMP-compliant production in only four months to support Phase III trials. This drew on our deep experience of manufacturing drug delivery systems and required redeploying R&D and engineering capabilities, as well as fast-tracking significant capital expenditure. Once, the Pfizer-BioNTech COVID-19 vaccine received regulatory approval, Croda/Avanti secured a contract to supply critical delivery system components.
“We were delighted to play a central role in the scale up of the Pfizer-BioNTech COVID-19 vaccine, achieved in unprecedented time, to enable delivery at pace - an exciting moment in the development of lipid drug delivery systems,” says Steve Burgess, Chief Scientific Officer at Avanti Polar Lipids. “We combined Avanti’s expertise in enabling drug products to be delivered into the body with Croda’s experience in the complex processes required to produce large volumes for a worldwide rollout.”
We have a...
Highly differentiated approach: Flexible, local manufacturing providing resilience, and direct selling to customers.
High-quality business with superior financial performance: Highly cash-generative operations with world-class profit margins.
Strong balance sheet: Clear capital allocation policy prioritising disciplined investment in growth.
Reputation for attractive shareholder returns: Track record of creating shareholder value through high returns on capital and 29 years of consecutive dividend progression.
Total shareholder return (TSR)
Sustainability spans every area of our business and is a crucial way we add value to our customers.Find out more
Through our product portfolio we have access to the broadest range of formulation ingredients and formulation know-how, which allows our customers to get the best performance out of their products.Find out more
Developing and delivering innovative, sustainable ingredients is at the heart of our business.Find out more